World Journal of Gastrointestinal Pharmacology and Therapeutics

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 29

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4883)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

HTML

3148

Figures (1-3)

122

Tables (1-5)

345

Sum=3679

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

173

Download

249

Sum=422

Publishing Process of This Article

Item

Count

Browse

Download

170

Sum=257

Aug 7, 2025 (publication date) through Nov 20, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Imbrizi M, Azevedo MFC, Baima JP, Queiroz NSF, Parra RS, Ferreira SDC, Sassaki LY, Chebli JMF. Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice. World J Gastroenterol 2025; 31(29): 107745 [PMID: 40809925 DOI: 10.3748/wjg.v31.i29.107745]
URL:	https://www.wjgnet.com/2150-5349/full/v31/i29/107745.htm

Number	Citing Articles
1	Iago Rodríguez-Lago, Fernando Muñoz Núñez, Alfredo J. Lucendo, Alfonso De Lossada Juste, Ana Cabez, Alberto de la Cuadra-Grande, Itziar Oyagüez, Emilio Monte-Boquet. Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain. PharmacoEconomics - Open 2025; doi: 10.1007/s41669-025-00619-6

Number

Citing Articles

Iago Rodríguez-Lago, Fernando Muñoz Núñez, Alfredo J. Lucendo, Alfonso De Lossada Juste, Ana Cabez, Alberto de la Cuadra-Grande, Itziar Oyagüez, Emilio Monte-Boquet. Cost-Effectiveness Analysis of Etrasimod Compared With Biologic Therapies for the Treatment of Patients with Moderately-to-Severely Active Ulcerative Colitis in Spain. PharmacoEconomics - Open 2025; doi: 10.1007/s41669-025-00619-6